# A Study of JR-171 in Patients With Mucopolysaccharidosis I

> **NCT04227600** · PHASE1,PHASE2 · COMPLETED · sponsor: **JCR Pharmaceuticals Co., Ltd.** · enrollment: 18 (actual)

## Conditions studied

- Mucopolysaccharidosis I

## Interventions

- **DRUG:** JR-171 (lepunafusp alfa)

## Key facts

- **NCT ID:** NCT04227600
- **Lead sponsor:** JCR Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-01
- **Primary completion:** 2022-08-02
- **Final completion:** 2022-08-02
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04227600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04227600, "A Study of JR-171 in Patients With Mucopolysaccharidosis I". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT04227600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*